Phase II trial of docetaxel and liposomal doxorubicin (Doxil) chemotherapy combined with enoxaparin in patients with advanced pancreatic cancer.

Trial Profile

Phase II trial of docetaxel and liposomal doxorubicin (Doxil) chemotherapy combined with enoxaparin in patients with advanced pancreatic cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Docetaxel; Doxorubicin liposomal; Enoxaparin sodium
  • Indications Pancreatic cancer; Thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Apr 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Planned end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 16 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top